Innovent Biologics (HK:1801)
:1801
Want to see HK:1801 full AI Analyst Report?
Total Valuation
Innovent Biologics has a market cap or net worth of HK$160.42B. The enterprise value is HK$124.51B.
Market CapHK$160.42B
Enterprise ValueHK$124.51B
Share Statistics
Innovent Biologics has 1,735,191,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,735,191,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Innovent Biologics’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 6.41%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)6.41%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee2.24M
Profits Per Employee148.25K
Employee Count5,659
Asset Turnover0.34
Inventory Turnover1.31
Valuation Ratios
The current PE Ratio of Innovent Biologics is ―. Innovent Biologics’s PEG ratio is -0.16.
PE Ratio―
PS Ratio9.04
PB Ratio5.93
Price to Fair Value5.93
Price to FCF12.33
Price to Operating Cash Flow7.54
PEG Ratio-0.16
Income Statement
In the last 12 months, Innovent Biologics had revenue of 12.70B and earned 792.51M in profits. Earnings per share was 0.48.
Revenue12.70B
Gross Profit10.99B
Operating Income1.97B
Pretax Income817.21M
Net Income792.51M
EBITDA1.97B
Earnings Per Share (EPS)0.48
Cash Flow
In the last 12 months, operating cash flow was 9.66B and capital expenditures -228.17M, giving a free cash flow of 9.43B billion.
Operating Cash Flow9.66B
Free Cash Flow9.43B
Free Cash Flow per Share5.44
Dividends & Yields
Innovent Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.64
52-Week Price Change69.43%
50-Day Moving Average84.91
200-Day Moving Average88.59
Relative Strength Index (RSI)59.02
Average Volume (3m)16.11M
Important Dates
Innovent Biologics upcoming earnings date is Aug 26, 2026, TBA (Confirmed).
Last Earnings DateMar 26, 2026
Next Earnings DateAug 26, 2026
Ex-Dividend Date―
Financial Position
Innovent Biologics as a current ratio of 2.62, with Debt / Equity ratio of 14.55%
Current Ratio2.62
Quick Ratio2.47
Debt to Market Cap0.02
Net Debt to EBITDA-7.38
Interest Coverage Ratio25.40
Taxes
In the past 12 months, Innovent Biologics has paid 24.70M in taxes.
Income Tax24.70M
Effective Tax Rate0.03
Enterprise Valuation
Innovent Biologics EV to EBITDA ratio is 50.96, with an EV/FCF ratio of 10.77.
EV to Sales7.90
EV to EBITDA50.96
EV to Free Cash Flow10.77
EV to Operating Cash Flow10.03
Balance Sheet
Innovent Biologics has HK$18.24B in cash and marketable securities with HK$2.82B in debt, giving a net cash position of HK$15.42B billion.
Cash & Marketable SecuritiesHK$18.24B
Total DebtHK$2.82B
Net CashHK$15.42B
Net Cash Per ShareHK$8.89
Tangible Book Value Per ShareHK$11.10
Margins
Gross margin is 82.26%, with operating margin of 15.50%, and net profit margin of 6.24%.
Gross Margin82.26%
Operating Margin15.50%
Pretax Margin6.43%
Net Profit Margin6.24%
EBITDA Margin15.50%
EBIT Margin15.50%
Analyst Forecast
The average price target for Innovent Biologics is HK$118.11, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$118.11
Price Target Upside29.08% Upside
Analyst ConsensusStrong Buy
Analyst Count15
Revenue Growth Forecast38.55%
EPS Growth Forecast―